Volatility and Risk
Windtree Therapeutics is less volatile than the S&P 500 with a beta of 0.55, while INmune Bio is more volatile at a beta of 1.85.
Profitability
Here’s a comparison of Windtree Therapeutics and INmune Bio’s financial performance:
| Net Margins | Return on Equity | Return on Assets | |
| Windtree Therapeutics | N/A | -347.82% | -81.41% |
| INmune Bio | -26,333.59% | -103.56% | -68.94% |
Earnings & Valuation
Comparing their revenue and earnings:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Windtree Therapeutics | N/A | N/A | -$20.29 million | ($36.29) | -0.03 |
| INmune Bio | $85,000.00 | 1,189.25 | -$30.01 million | ($1.92) | -2.66 |
Windtree has higher earnings but lower revenue compared to INmune Bio. Currently, INmune Bio has a more attractive price-to-earnings ratio.
Analyst Recommendations
Current ratings for both companies are summarized below:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Windtree Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
| INmune Bio | 0 | 0 | 2 | 0 | 3.00 |
INmune Bio has a target price of $20.00, suggesting a potential increase of 291.39%. Analysts favor INmune Bio over Windtree Therapeutics.
Insider and Institutional Ownership
Institutional investors hold 29.3% of Windtree Therapeutics and 12.7% of INmune Bio, with insiders owning 0.5% and 35.2% respectively. Higher institutional ownership often indicates a belief in a stock’s long-term growth potential.
Summary
INmune Bio outperforms Windtree Therapeutics in 9 of the 13 factors evaluated.
About Windtree Therapeutics
Windtree Therapeutics focuses on therapies for acute cardiovascular diseases, with products like istaroxime in clinical trials for heart failure.
About INmune Bio
INmune Bio works on drugs that enhance the immune system for diseases, with candidates like INKmune in development.
Receive Daily News & Ratings for Windtree Therapeutics – Enter your email below to get a summary of the latest news and ratings.
